pyrazines has been researched along with Metabolic Syndrome in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aday, AW; Beckman, JA; Goldfine, AB; Gregory, JM | 1 |
| Diamant, M; Heymans, MW; Mari, A; Muskiet, MH; Ouwens, DM; Pouwels, PJ; van Genugten, RE; van Raalte, DH | 1 |
| Akcali, KC; Amber, CF; Belma, T; Bozkus, Y; Can, AK; Cicek, FA; Evren, O; Ozcinar, E; Tokcaer-Keskin, Z; Turan, B; Yusuf, B; Zeynep, TK | 1 |
| Cebrián, D; de Cabo, R; González-García, I; Gutierrez, VM; Iglesias, G; López, M; Lopez-Guadamillas, E; Martinez, S; Mattison, JA; Mitchell, SJ; Muñoz-Martin, M; Ortega-Molina, A; Pastor, J; Serrano, M; Szarowicz, MD; Vaughan, KL | 1 |
| Greenhill, C | 1 |
| Bilan, VP; Jackson, EK; Tofovic, DS | 1 |
| Aguila, MB; Cardoso-de-Lemos, FS; de Carvalho, L; Gregório, BM; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Jackson, EK | 1 |
| Brown, NJ; Byrne, L; Kunchakarra, S; Marney, A | 1 |
| Borelli, MI; Del Zotto, H; Flores, LE; Francini, F; Gagliardino, JJ; Madrid, VG; Maiztegui, B; Massa, ML; Raschia, MA; Rebolledo, OR | 1 |
| Bergamini, E; Bertolotto, M; Dallegri, F; Delrio, A; Franciosi, U; Lenglet, S; Mach, F; Minetti, S; Montecucco, F; Ottonello, L; Pelli, G; Pende, A; Puddu, A; Quercioli, A; Viviani, GL; Vuilleumier, N | 1 |
| Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R | 1 |
5 trial(s) available for pyrazines and Metabolic Syndrome
| Article | Year |
|---|---|
Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Fatty Acids, Nonesterified; Female; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Pyrazines; Vasodilation | 2019 |
Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Glucocorticoids; Glucose Intolerance; Humans; Insulin Resistance; Islets of Langerhans; Male; Metabolic Syndrome; Middle Aged; Postprandial Period; Prednisolone; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enalapril; Female; Heart Rate; Hemodynamics; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Peptidyl-Dipeptidase A; Prospective Studies; Pyrazines; Renal Circulation; Sitagliptin Phosphate; Sodium; Triazoles | 2010 |
Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome.
Topics: Administration, Oral; Adult; Algorithms; Cells, Cultured; Down-Regulation; Female; Humans; Hypolipidemic Agents; Inflammation; Insulin; Male; Metabolic Syndrome; Middle Aged; Neutrophils; Pyrazines; Time Factors | 2011 |
The metabolic syndrome influences the response to incretin-based therapies.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2011 |
8 other study(ies) available for pyrazines and Metabolic Syndrome
| Article | Year |
|---|---|
Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation.
Topics: Analysis of Variance; Animals; Aorta; Blotting, Western; Dipeptidyl-Peptidase IV Inhibitors; Epigenesis, Genetic; Fluorescent Antibody Technique; Histones; Metabolic Syndrome; Pyrazines; Rats; Sitagliptin Phosphate; Sucrose; Triazoles; Vasodilation | 2014 |
Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.
Topics: Adiposity; Animals; Histological Techniques; Imidazoles; Immunoblotting; Indazoles; Liver; Macaca mulatta; Mass Spectrometry; Metabolic Syndrome; Mice, Obese; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; Sulfonamides | 2015 |
Obesity: Inhibiting PI3K reduces body weight in obese mice.
Topics: Adiposity; Animals; Imidazoles; Indazoles; Metabolic Syndrome; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; Sulfonamides | 2015 |
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.
Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Hypertension; Kidney; Male; Metabolic Syndrome; Proteinuria; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sitagliptin Phosphate; Triazoles; Vasoconstriction; Vasoconstrictor Agents | 2010 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Energy Intake; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2010 |
Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Enalapril; Heart Rate; Hemodynamics; Humans; Metabolic Syndrome; Models, Biological; Peptidyl-Dipeptidase A; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drinking; Drug Evaluation, Preclinical; Eating; Exenatide; Fatty Liver; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metabolic Syndrome; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
[Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Metabolic Syndrome; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sitagliptin Phosphate; Survival Rate; Triazoles | 2012 |